{'fraction_non_alphanumeric': 0.029782359679266894, 'fraction_numerical': 0.004581901489117984, 'mean_word_length': 6.47008547008547, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Suppressing myocardial fibrosis to promote myocardial regeneration as a therapeutic strategy for chronic cardiovascular diseases].

Abnormal cardiovascular tissue remodeling characterized by myocardial hypertrophy, myocardial cell loss and myocardial fibrosis, are the primary pathological changes for multiple cardiovascular diseases. Targeting tissue remodeling using small molecules (e.g., relaxin, KNK437), biological agents (e.g., BCG, anti-TLR2 antibody), or herb medicine complex CFX and so on, can attenuate tissue fibrosis and improve cardiac functions. Therefore, regulating the property of inflammation and reversing tissue fibrosis should promote the formation of optimal tissue environments for stem cells mobilization and proliferation, which enhances the myocardial regeneration and is potential therapeutic strategy against chronic cardiovascular diseases.